Stock SNBP PANBELA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Panbela Therapeutics, Inc.

Equities

SNBP

US69833W4042

Market Closed - OTC Markets
Other stock markets
 20:52:50 26/06/2024 BST 		5-day change 1st Jan Change
0.3813 USD -0.97% Intraday chart for Panbela Therapeutics, Inc. -5.85% -97.92%
06-24 Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification CI
06-10 Panbela Therapeutics, Inc. Announces Oral Presentation at Digestive Disease Week CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
GL
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
AQ
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
CI
Panbela Announces Oral Presentation at Digestive Disease Week (DDW)
GL
Panbela Announces Oral Presentation at Digestive Disease Week (DDW)
AQ
Panbela Therapeutics, Inc. Announces Oral Presentation at Digestive Disease Week
CI
North American Morning Briefing : The "Everything -2-
DJ
Transcript : Panbela Therapeutics, Inc., Q1 2024 Earnings Call, May 15, 2024
Panbela Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Panbela Provides Business Update and Reports Q1 2024 Financial Results
AQ
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
GL
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
GL
Certain Stock Options of Panbela Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.
CI
Certain Warrants of Panbela Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.
CI
Certain Common Stock of Panbela Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.
CI
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
GL
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
GL
Panbela Therapeutics, Inc. Announces Interim Data Analysis for its Ongoing ASPIRE Trial Pushed to First Quarter of 2025
CI
Panbela Announces Poster Presentation at American Association for Cancer Research
AQ
Panbela Announces Poster Presentation at American Association for Cancer Research
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SNBP Stock
  4. News Panbela Therapeutics, Inc.